Ensysce Biosciences, Inc. (NASDAQ:ENSC) Short Interest Update

Ensysce Biosciences, Inc. (NASDAQ:ENSCGet Free Report) saw a large decline in short interest during the month of November. As of November 30th, there was short interest totalling 115,300 shares, a decline of 97.6% from the November 15th total of 4,850,000 shares. Based on an average trading volume of 1,760,000 shares, the short-interest ratio is presently 0.1 days.

Ensysce Biosciences Price Performance

ENSC stock traded down $0.50 during mid-day trading on Friday, hitting $5.62. 133,770 shares of the stock were exchanged, compared to its average volume of 534,941. Ensysce Biosciences has a 12 month low of $2.12 and a 12 month high of $30.90. The business has a fifty day moving average price of $6.93 and a 200 day moving average price of $6.66. The stock has a market capitalization of $7.36 million, a price-to-earnings ratio of -0.20 and a beta of 0.60.

Ensysce Biosciences (NASDAQ:ENSCGet Free Report) last released its quarterly earnings data on Tuesday, November 12th. The company reported $1.05 earnings per share for the quarter, beating analysts’ consensus estimates of ($4.50) by $5.55. Ensysce Biosciences had a negative return on equity of 292.81% and a negative net margin of 179.26%. The firm had revenue of $3.42 million during the quarter, compared to analyst estimates of $0.25 million. As a group, equities analysts forecast that Ensysce Biosciences will post -12.44 EPS for the current fiscal year.

Hedge Funds Weigh In On Ensysce Biosciences

A hedge fund recently bought a new stake in Ensysce Biosciences stock. Anson Funds Management LP purchased a new stake in shares of Ensysce Biosciences, Inc. (NASDAQ:ENSCFree Report) in the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 983,518 shares of the company’s stock, valued at approximately $236,000. Anson Funds Management LP owned about 11.15% of Ensysce Biosciences at the end of the most recent reporting period. 5.63% of the stock is currently owned by hedge funds and other institutional investors.

About Ensysce Biosciences

(Get Free Report)

Ensysce Biosciences, Inc, a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection (TAAP) platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance (MPAR) platform, an over-dose protection opioid prodrug technology.

Featured Articles

Receive News & Ratings for Ensysce Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ensysce Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.